Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax (Nasdaq: NVAX) announced that Dr. Gregory Glenn will present updates on NVX-CoV2373, its coronavirus vaccine candidate, during a COVID-19 webinar on May 13, 2020. This informative session is part of the World Vaccine Congress and aims to address ongoing global vaccine development efforts. NVX-CoV2373, engineered from the SARS-CoV-2 sequence, uses recombinant nanoparticle technology to generate effective immune responses. A Phase 1 clinical trial is set to begin in May 2020, with initial results expected by July. CEPI has provided $4 million to support this initiative.